A survey of women diagnosed with breast cancer experiencing oncology treatment–induced hot flushes: identification of specific characteristics as predictors of hot flush occurrence, frequency, and severity

Gallagher, S; Johnstone, A; De Livera, A; Marsh, DJ; Walsh, S

A survey of women diagnosed with breast cancer experiencing oncology treatment–induced hot flushes: identification of specific characteristics as predictors of hot flush occurrence, frequency, and severity

Gallagher, S Johnstone, A De Livera, A Marsh, DJ Walsh, S

Permalink

Publisher:: Springer
Publication Type:: Journal Article
Citation:: Journal of Cancer Survivship, 2024, 2024
Issue Date:: 2024-08-01

Open Access

Copyright Clearance Process

Recently Added
In Progress
Open Access

This item is open access.

Adobe PDF

Download Published versionAdobe PDF (799.1 kB)

View statistics

Full metadata record

Field	Value	Language
dc.contributor.author	Gallagher, S
dc.contributor.author	Johnstone, A
dc.contributor.author	De Livera, A
dc.contributor.author	Marsh, DJ
dc.contributor.author	Walsh, S
dc.date.accessioned	2024-08-01T02:08:43Z
dc.date.available	2024-08-01T02:08:43Z
dc.date.issued	2024-08-01
dc.identifier.citation	Journal of Cancer Survivship, 2024, 2024
dc.identifier.uri	http://hdl.handle.net/10453/179889
dc.description.abstract	Purpose: More women diagnosed with breast cancer (BC) are living with oncology treatment–induced hot flushes (HFs). This Australian-based survey explores why some women experience more severe or ongoing HF and whether specific population characteristics are predictive of HF occurrence, frequency, and/or severity. Methods: A non-probabilistic anonymous survey distributed online (Register4) and two Australian hospitals collected demographic and clinical information. Eligibility was consenting Australian-based women, 18 years and over, with a primary BC diagnosis. Analysis included linear and logistic regression models. Results: A total of 324 survey responses were analyzed. Chemotherapy and hormone therapy were each associated with HF occurrence (aOR = 2.92, 95% CI [1.27, 6.70], p = 0.01; and aOR = 7.50, 95% CI [3.02, 18.62], p < 0.001) and in combination (aOR = 5.98, 95% CI [2.61, 13.69], p < 0.001). Increased self-reported anxiety at BC diagnosis was significantly associated with HF frequency and severity scores (aCO = 0.71, 95% CI [0.31, 1.12], p = 0.001; and aCO = 0.44, 95% CI [0.33, 0.55], p < 0.001). Postmenopausal women had significantly lower HF severity and frequency scores than premenopausal women (aCO = −0.93, 95% CI [−1.62, −0.25], p = 0.008; and aCO = −2.62, 95% CI [−5.14, −0.11], p = 0.041). Conclusions: Women with BC receiving chemotherapy and/or hormone therapy and premenopausal or experiencing elevated anxiety and/or stress will likely experience more severe oncology treatment–related HFs. Implications for Cancer Survivors: HFs continue across the BC treatment trajectory with women >5-year survivorship still reporting life impacts, with premenopausal women at the time of BC diagnosis at higher risk of experiencing severe and more frequent oncology treatment-induced HFs than postmenopausal women. Women at high risk require information on methods to moderate HF potential life impacts and maintain treatment compliance.
dc.language	en
dc.publisher	Springer
dc.relation.ispartof	Journal of Cancer Survivship
dc.rights	info:eu-repo/semantics/openAccess
dc.title	A survey of women diagnosed with breast cancer experiencing oncology treatment–induced hot flushes: identification of specific characteristics as predictors of hot flush occurrence, frequency, and severity
dc.type	Journal Article
utslib.citation.volume	2024
pubs.organisational-group	University of Technology Sydney
pubs.organisational-group	University of Technology Sydney/Provost
pubs.organisational-group	University of Technology Sydney/Provost/TD School
utslib.copyright.status	open_access	*
pubs.consider-herdc	true
dc.rights.license	This work is licensed under a Creative Commons Attribution 4.0 International License (CC BY 4.0). To view a copy of this license, visit https://creativecommons.org/licenses/by/4.0/
dc.date.updated	2024-08-01T02:08:41Z
pubs.publication-status	Published online
pubs.volume	2024

Abstract:

Purpose: More women diagnosed with breast cancer (BC) are living with oncology treatment–induced hot flushes (HFs). This Australian-based survey explores why some women experience more severe or ongoing HF and whether specific population characteristics are predictive of HF occurrence, frequency, and/or severity. Methods: A non-probabilistic anonymous survey distributed online (Register4) and two Australian hospitals collected demographic and clinical information. Eligibility was consenting Australian-based women, 18 years and over, with a primary BC diagnosis. Analysis included linear and logistic regression models. Results: A total of 324 survey responses were analyzed. Chemotherapy and hormone therapy were each associated with HF occurrence (aOR = 2.92, 95% CI [1.27, 6.70], p = 0.01; and aOR = 7.50, 95% CI [3.02, 18.62], p < 0.001) and in combination (aOR = 5.98, 95% CI [2.61, 13.69], p < 0.001). Increased self-reported anxiety at BC diagnosis was significantly associated with HF frequency and severity scores (aCO = 0.71, 95% CI [0.31, 1.12], p = 0.001; and aCO = 0.44, 95% CI [0.33, 0.55], p < 0.001). Postmenopausal women had significantly lower HF severity and frequency scores than premenopausal women (aCO = −0.93, 95% CI [−1.62, −0.25], p = 0.008; and aCO = −2.62, 95% CI [−5.14, −0.11], p = 0.041). Conclusions: Women with BC receiving chemotherapy and/or hormone therapy and premenopausal or experiencing elevated anxiety and/or stress will likely experience more severe oncology treatment–related HFs. Implications for Cancer Survivors: HFs continue across the BC treatment trajectory with women >5-year survivorship still reporting life impacts, with premenopausal women at the time of BC diagnosis at higher risk of experiencing severe and more frequent oncology treatment-induced HFs than postmenopausal women. Women at high risk require information on methods to moderate HF potential life impacts and maintain treatment compliance.

Please use this identifier to cite or link to this item:

http://hdl.handle.net/10453/179889